1. Home
  2. BBW vs LRMR Comparison

BBW vs LRMR Comparison

Compare BBW & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BBW

Build-A-Bear Workshop Inc.

HOLD

Current Price

$33.06

Market Cap

444.3M

ML Signal

HOLD

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

HOLD

Current Price

$3.10

Market Cap

455.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBW
LRMR
Founded
1997
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
444.3M
455.8M
IPO Year
2004
2014

Fundamental Metrics

Financial Performance
Metric
BBW
LRMR
Price
$33.06
$3.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
6
Target Price
$67.71
$16.50
AVG Volume (30 Days)
346.5K
1.7M
Earning Date
05-28-2026
05-06-2026
Dividend Yield
2.51%
N/A
EPS Growth
5.00
N/A
EPS
3.99
N/A
Revenue
$357,866,000.00
N/A
Revenue This Year
$5.63
N/A
Revenue Next Year
$4.62
$1,816.14
P/E Ratio
$8.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.96
$2.26
52 Week High
$75.77
$6.42

Technical Indicators

Market Signals
Indicator
BBW
LRMR
Relative Strength Index (RSI) 33.69 30.91
Support Level N/A $2.72
Resistance Level $39.83 $3.74
Average True Range (ATR) 2.00 0.18
MACD -0.31 -0.01
Stochastic Oscillator 3.37 8.66

Price Performance

Historical Comparison
BBW
LRMR

About BBW Build-A-Bear Workshop Inc.

Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments: Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, U.K., Ireland, and two e-commerce sites, the international franchising segment includes royalties and product and fixture sales from other international operations under franchise agreements, and the commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: